Bluestein R H & Co. bought a new position in Hologic, Inc. (NASDAQ:HOLX) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 7,800 shares of the medical equipment provider’s stock, valued at approximately $291,000.
Several other institutional investors and hedge funds have also recently made changes to their positions in HOLX. Parnassus Investments CA boosted its holdings in shares of Hologic by 88.6% in the fourth quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock worth $608,797,000 after buying an additional 6,689,454 shares during the period. Two Sigma Advisers LP boosted its holdings in shares of Hologic by 28.1% in the fourth quarter. Two Sigma Advisers LP now owns 2,828,311 shares of the medical equipment provider’s stock worth $120,910,000 after buying an additional 620,761 shares during the period. Guggenheim Capital LLC boosted its holdings in shares of Hologic by 46.0% in the fourth quarter. Guggenheim Capital LLC now owns 1,662,053 shares of the medical equipment provider’s stock worth $71,053,000 after buying an additional 523,654 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of Hologic in the fourth quarter worth about $18,383,000. Finally, Victory Capital Management Inc. boosted its holdings in shares of Hologic by 5.8% in the fourth quarter. Victory Capital Management Inc. now owns 6,199,017 shares of the medical equipment provider’s stock worth $265,008,000 after buying an additional 342,239 shares during the period. Institutional investors own 99.80% of the company’s stock.
In other news, VP Karleen Marie Oberton sold 12,196 shares of Hologic stock in a transaction that occurred on Wednesday, May 2nd. The shares were sold at an average price of $40.00, for a total value of $487,840.00. Following the transaction, the vice president now owns 13,825 shares of the company’s stock, valued at $553,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Allison P. Bebo sold 7,000 shares of Hologic stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $38.75, for a total transaction of $271,250.00. The disclosure for this sale can be found here. Company insiders own 0.79% of the company’s stock.
Several research analysts have commented on the stock. Leerink Swann cut shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $48.00 to $41.00 in a report on Thursday, May 3rd. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Friday. BTIG Research reiterated a “buy” rating and issued a $44.00 target price on shares of Hologic in a report on Sunday, May 6th. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 target price on shares of Hologic in a report on Friday, February 9th. Finally, Zacks Investment Research cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Monday, April 30th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $44.87.
Shares of Hologic opened at $38.92 on Friday, according to MarketBeat. The company has a market cap of $10.60 billion, a P/E ratio of 19.17, a price-to-earnings-growth ratio of 1.83 and a beta of 0.87. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.98 and a current ratio of 1.26. Hologic, Inc. has a twelve month low of $35.10 and a twelve month high of $46.80.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.53. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The company had revenue of $789.30 million for the quarter, compared to analyst estimates of $781.23 million. During the same quarter last year, the firm posted $0.50 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. analysts predict that Hologic, Inc. will post 2.24 earnings per share for the current year.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.